PRA International Expands European Presence With Opening of Mun... (ascular and Infectious Diseases weperfor...)

(Date:1/8/2009)...Jan. 8 The Alliance for...poses the new marketing campaigns by Wal-Mart, Sto...vide free prescribed antibiotics to customers. The...ll actually lead to increased costs in the form of...ce. While the public,s need for affordable health...

(Date:1/8/2009)...Jan. 8 A study released this week ...fering from multiple chronic diseases shines a muc...ealth care system to one that focuses on primary a...ive Medicine, the leader in disease prevention. ...h/20080506/NETU129LOGO ) , , The study, condu...

(Date:1/8/2009)...ia Assembly Member Tom Torlakson Introduces AB 89 ...wswire/ -- Today, Lung Cancer Alliance-Californi...Torlakson (D-11th District) for his continued lead...g for lung cancer research. For the third consecu... research is being considered in the California Le...

(Date:1/8/2009)...quick to condemn hurtful comments, study suggests ...- Many people overestimate how strongly they would... , Sixty-three percent of study participants at...er for an experiment with a white person rather th...acist comments about the black person when he left...

Breaking Medicine News(10 mins):Health News:Antibiotics as Loss Leaders? 2 Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2 Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2 Health News:Many Turn Blind Eye to Racism 2

[0] Antibiotics as Loss Leaders?[0] U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention [0] Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research [0] Many Turn Blind Eye to Racism

...en from 55 countries who will be the fourth Intern... four-day international congress titled "WWH-2005"...st time in South Asia. The earlier meetings were h...de Janeiro (1999) and Stockholm (2002). Among its ...

...sing the cholesterol level in blood.High level of ... in moderate amounts, can lead to serious health r...n of University College London examined 199 health...how individuals react to stress and whether their ...

...s have successfully treated nerve damage in mice b...stem cells, and hope to treat patients with an inj...n future.// The results of the new research sugges...ervous axon growth and functional recovery after n...

..., the families of more than 1,200 children, whose ...nts' knowledge ,will each receive Compensations.//...eal announced recently ,in the United Kingdom. Th...ht the cases involving organ-retention at 146 hosp...

Other Medicine News:Health News:Delhi To Host International Women’s Congress From Nov 2 2 Health News:Stem Cells From Hair Follicle To Repair Nerve Damage 2 Health News:Organ Scandals Compensation And The Aftermath 2

Delhi To Host International Women’s Congress From Nov 2 Stress Is A Factor In Cholesterol Level Stem Cells From Hair Follicle To Repair Nerve Damage Organ Scandals Compensation And The Aftermath

(Date:1/8/2009)...ated at the initial dose in an ongoing Phase Ib tr...line after three days , , Conference Call Today...re-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nas...st cohort of an ongoing Phase Ib clinical trial of...ide polymerase inhibitor. ANA598 was very well-to...

(Date:1/7/2009)...n., Jan. 7 Scientists h...high likelihood of relapse in children with acute ...hers caution that further research is needed to de... IKAROS, lead to leukemia relapse, the findings ...tic tests to assess the risk of treatment failure....

(Date:1/7/2009)...d., Jan. 7 ImQuest Life Sciences a... application to the Food and Drug Administration t...rimidinedione HIV inhibitor IQP-0410. ImQuest anti...rst quarter of 2009. IQP-0410 is a novel small mol...onnucleoside reverse transcriptase inhibitor (NNRT...

(Date:1/7/2009).... 7 Tiantan Puhua Hospital Stem Ce...worldwide leader in using stem cells to effectivel...x new globally experienced additions to its medica... hospital,s treatment capabilities for growing num...enior doctors include the distinguished Dr. Jiang ...

Breaking Medicine Technology:ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5 ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6 Gene Abnormality Found to Predict Childhood Leukemia Relapse 2 Gene Abnormality Found to Predict Childhood Leukemia Relapse 3 Gene Abnormality Found to Predict Childhood Leukemia Relapse 4 Gene Abnormality Found to Predict Childhood Leukemia Relapse 5 Gene Abnormality Found to Predict Childhood Leukemia Relapse 6 ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 2 Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 2 Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients 3 Continuous Blood Pressure Monitoring Predicts Risks 30515 1 Continuous Blood Pressure Monitoring Predicts Risks 30515 2 Continuous Blood Pressure Monitoring Predicts Risks 30515 3 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 1 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 2 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 3 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 4 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 5 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 6 11 4 25 Shareholders 26 Former Executive Management of LCA Vision Express Shock and Disbelief at Recent Adoption of Poison Pill 30512 7 Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 1 Thermage Schedules Shareholder Meeting for Vote on the Issuance of Common Stock in Connection With the Reliant Acquisition 30509 2 Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 1 Foundation Venture Capital Group Invests in Company Working to Protect Healthy Tissue During Cancer Treatment 30506 2

[0] ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients [1] Gene Abnormality Found to Predict Childhood Leukemia Relapse [0] ImQuest Submits Investigational New Product Application to the Food and Drug Administration to Initiate HIV Therapeutic Clinical Trials with IQP-0410 [0] Stem Cell Treatment Leader Tiantan Puhua Adds Experienced International Medical Staff for Expanding Numbers of Patients

...3, 2007 - Affymax, Inc.,(Nasdaq:AFFY) today announ...ical trials of Hematide(TM) in dialysis and,non-di...data showed,that in treatment naive, non-dialysis ...stered monthly at an appropriate dose.,Similarly, ...ith,three-times weekly Epoetin Alfa demonstrated t...

...7 - CytRx Corporation,(NASDAQ:CYTR) today announce...logy exclusively licensed to its majority-owned,su...as been,published in the April 2007 issue of peer-...The technology was developed by RXi,Co-founder, Sc...assachusetts Medical School (UMMS) Professor of Bi...

Other Medicine Technology:Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 2 Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease 3 CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 2 CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 3 CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal 4

Affymax Announces Phase 2 Clinical Trial Results of Once-Per-Month,Hematide for the Treatment of Anemia in Patients with Early- and,End-Stage Chronic Kidney Disease CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively,Licensed to Subsidiary, RXi Pharmaceuticals, Described in,Peer-Reviewed Journal

...LY-CLARK CLOtest Rapid Urease Test is recognized b...g urease tests because of its accuracy, convenienc...y Marshall, MD. who, along with Robin Warren, M.D.... H. pylori and gastric ulcers. Today, CLOtest has ...

Serim PyloriTek Test Kit detects urease activity in gastric biopsy specimens for the presumptive identification of an Helicobacter pylori infection.

...ickVue H.pylori gII test is a lateral-flow immuno-...itative detection of IgG antibodies specific to He...blood. It utilizes a convenient, non-invasive, and...s in the diagnosis of H.pylori infection in patien...

...re HP is a visually read, qualitative immunochroma... to H. pylori, a bacterium that grows in the stoma... some gastric cancers. FlexSure HP, available for ...ides the physician with the opportunity to perform...

Medicine Products:

CLOtest Rapid Urease Test SERIM PYLORITEK VP TEST KIT QuickVue H.pylori gII test FlexSure HP

PRA International Expands European Presence With Opening of Mun...(ascular and Infectious Diseases weperfor...),Health